组蛋白去乙酰化酶抑制剂对多发性骨髓瘤细胞的杀伤机制及临床应用现状  

Clinical application status and killing mechanism of histone deacetylase inhibitors for multiple myeloma cells

作　　者：苑冬阳 高欣 杨融辉[1] 张萌[1] 廖爱军[1] Dongyang Yuan;Xin Gao;Ronghui Yang;Meng Zhang;Aijun Liao(Department of Hematology,Shengjing Hospital of China Medical University,Shenyang 110020,China)

机构地区：[1]中国医科大学附属盛京医院血液科,沈阳市110020

出　　处：《中国肿瘤临床》2018年第13期691-694,共4页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:81272629);沈阳市科技计划项目(编号:17-231-1-58)资助~~

摘　　要：多发性骨髓瘤(multiple myeloma,MM)是恶性浆细胞瘤,至今无法治愈。在过去的20年中,蛋白酶体抑制剂(proteasome inhibitors,PIs)硼替佐米和免疫调节剂(immunomodulatory drug,IMi D)来那度胺显著改善了MM患者的预后,延长了MM患者的生存时间。组蛋白去乙酰化酶抑制剂(histone deacetylase inhibitors,HDACis)具有较好的抗MM活性,可以显著提高MM患者治疗的总有效率(overall response rate,ORR),延长MM患者的无进展生存期(progression free survival,PFS)和总生存期(overall survival,OS)。而对既往应用IMi D或PIs耐药的患者,HDACis仍能取得较好的疗效。本文就HDACis作用于MM细胞的杀伤机制以及临床中对MM的治疗效果进行综述。Multiple myeloma（MM） is a malignant plasmacytoma that remains incurable. Over the past two decades, with the advent of proteasome inhibitors（PIs）, such as bortezomib, and immunomodulatory drugs, such as lenalidomide, the prognosis of MM patients has been significantly improved and their survival time has been prolonged. Recent studies have shown that histone deacetylase inhibitors（HDACis） seems to have better anti-myeloma activity and can significantly improve the overall response rate and prolong both progression-free survival and overall survival of MM patients. Moreover, HDACis can also achieve better efficacy in patients previously treated with an immunomodulatory drug or PIs and those displaying resistance to them. This paper aims to summarize the killing mechanism of HDACis in MM cells and its therapeutic effect on MM patients.

关 键 词：多发性骨髓瘤 组蛋白去乙酰化酶抑制剂 复发 难治 蛋白酶体抑制剂 

分 类 号：R733.3[医药卫生—肿瘤]